Asociación Mexicana de Orientación, Apoyo y Lucha Contra la Esclerodermia

Asociación Mexicana de Orientación, Apoyo y Lucha Contra la Esclerodermia Fue constituida en el año 2002 con el fin de reunir a toda persona, hombres, mujeres y niños que p

Se realizan reuniones con el fin de intercambiar experiencias respecto a la enfermedad, tratamientos y forma de llevar la enfermedad con calidad de vida. También se invitan a médicos especializados que han tratado y conocen la sintomatología de la misma. Esta enfermedad no es muy común por lo que esta Asociación está tratando de difundir en centros de salud, en hospitales, clínicas públicas y priv

adas información al respecto, otro de los proyectos que se tienen es contactar con laboratorios y centros de investigación en universidades para que se hagan estudios a fondo sobre la enfermedad y así crear nuevos medicamentos para mejorar la expectativa y calidad de vida.

09/04/2026

¿Sabes cuáles son tus derechos laborales si tienes una enfermedad crónica? 🏢⚖️

Vivir con artritis u otra enfermedad crónica y mantener tu vida laboral parece a veces un reto, pero la ley te protege y te da opciones. En este artículo te explicamos qué adaptaciones puedes solicitar a tu empresa, cómo gestionar las bajas temporales o parciales y las citas médicas, así como reducciones de jornada o la protección de tu empleo y salud.

Tener una enfermedad crónica no tiene por qué significar renunciar a trabajar. ¡Infórmate y haz valer tus derechos! 💪

👉 Léelo en nuestro blog.
Enlace al artículo (link en bio): https://conartritis.org/trabajar-con-una-enfermedad-cronica/

09/04/2026

📢 Ampliamos el contenido del proyecto Reumafit con un nuevo material sobre sarcopenia en enfermedades reumáticas, en el marco del Día Mundial de la Actividad Física.

ℹ️ En este documento, se muestran los beneficios del ejercicio en la mejora del metabolismo muscular a través de múltiples vías: mecánica, hormonal, metabólica y regenerativa, mejorando la fuerza y la masa muscular.

📙 https://inforeuma.com/wp-content/uploads/2026/04/REUMAFIT_SARCOPENIA_Reduc.pdf

Es muy complicado tener calcinosisConsulta con tu médico
01/04/2026

Es muy complicado tener calcinosis
Consulta con tu médico

CALCINOSIS
Photo by Carolyn F.

This image shows calcinosis, where calcium deposits build up in the soft tissues, in this case at the fingertip. The deposit appears as a firm, yellowish material that can become visible through the skin.

Calcinosis occurs when calcium accumulates in areas such as the skin, fingers, or around joints. These deposits can develop gradually and may vary in size, number, and location depending on the individual.

In the fingers, calcinosis is often seen near the fingertips or pressure points. Over time, the deposits may move closer to the surface of the skin and become more noticeable or palpable.

Management approaches for calcinosis may include medications that aim to reduce inflammation, improve circulation, or address underlying conditions. In some cases, treatments may focus on softening deposits, preventing complications, or managing symptoms associated with the affected area.

Care strategies may also involve protecting the skin, minimizing pressure on affected areas, and maintaining overall tissue health. These approaches can be part of ongoing management depending on the individual’s condition and treatment plan.



01/04/2026

Prednisone is a medication commonly used in the management of inflammatory and autoimmune manifestations associated with systemic sclerosis (scleroderma). While scleroderma is primarily known for fibrosis and vascular involvement, inflammation can also play a role in symptoms such as joint pain, muscle involvement, and early skin changes. In some patients, this inflammation may contribute to discomfort, stiffness, and reduced mobility, affecting daily functioning and overall quality of life.

Prednisone works as a corticosteroid that suppresses the immune system and reduces inflammation throughout the body. By decreasing inflammatory activity, prednisone may help relieve joint pain, muscle inflammation, and swelling in certain individuals with systemic sclerosis. This effect can improve physical comfort and support better movement, particularly in patients with overlapping inflammatory features.

In patients with systemic sclerosis, prednisone is used cautiously to manage specific symptoms, especially when inflammation is present. However, its use requires careful consideration, as higher doses have been associated with an increased risk of complications such as scleroderma renal crisis. For this reason, healthcare providers typically prescribe the lowest effective dose for the shortest duration possible, balancing benefits and risks.

Clinical guidance and expert recommendations, including those from the European Alliance of Associations for Rheumatology, emphasize cautious use of corticosteroids in systemic sclerosis. Although prednisone can be helpful for inflammatory symptoms, it is not considered a primary treatment for the underlying disease process. Instead, it is often used as part of a broader, individualized treatment plan that may include immunosuppressive therapies and supportive care depending on the patient’s condition.

Despite its benefits, prednisone may cause side effects that require monitoring. Common side effects include weight gain, increased appetite, mood changes, elevated blood pressure, high blood sugar levels, and increased susceptibility to infections. Long-term use may also lead to bone thinning (osteoporosis), muscle weakness, and skin changes. Regular follow-up with healthcare providers is important to ensure safe and appropriate use.

Overall, prednisone plays a supportive and carefully monitored role in managing inflammatory symptoms in systemic sclerosis. Although it does not directly treat fibrosis or reverse the disease, it can help reduce inflammation and improve comfort when used under medical supervision.

References:
Christopher P. Denton, C. P., & Dinesh Khanna, D. (2017). Systemic sclerosis. The Lancet, 390(10103), 1685–1699.
European Alliance of Associations for Rheumatology. (2024). EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases.

Disclaimer:
This post is for educational and awareness purposes only and does not constitute medical advice. Prednisone is a prescription medication that should only be used under the supervision of qualified healthcare professionals. Treatment decisions should always be made in consultation with physicians experienced in systemic sclerosis and its complications.

01/04/2026
30/03/2026

Scleroderma affects everything, beginning with the body and extending far beyond it. At first, it may seem like a physical condition—tight skin, pain, fatigue, and internal complications—but over time, it becomes clear that it reaches into every part of life. What once felt simple can slowly become difficult, and what once felt certain can begin to shift.

Physically, the changes can be overwhelming. Movements that used to be effortless may require strength and patience. Breathing, digestion, circulation—systems we rarely think about—can become daily concerns. As a result, the body no longer feels like something you fully control, but rather something you must constantly listen to, adjust to, and care for in deeper ways.

At the same time, it affects emotional well-being. There are moments of courage and acceptance; however, there are also waves of fear, frustration, and quiet grief. Because the illness is unpredictable, it often brings anxiety about the future. Yet, despite this uncertainty, resilience slowly builds, teaching you how to hold both hope and hardship at once.

Moreover, scleroderma affects mental health and perspective. It can change how you see yourself and how you process the world around you. Over time, you may find yourself becoming more reflective, more patient, or even more aware of what truly matters. Still, there are days when the weight of everything feels heavy, and that, too, is part of the journey.

In addition, relationships are deeply affected. Some people may not fully understand what you’re going through, which can create distance or loneliness. However, those who choose to stay often become even more important. Through this, you begin to see who truly listens, who supports, and who stands beside you not only in the easy moments but especially in the difficult ones.

Likewise, independence can change in ways that are not always easy to accept. Tasks that once required no thought may now require help. Although this shift can feel frustrating, it also teaches a different kind of strength—the ability to accept support, to trust others, and to redefine independence not as doing everything alone, but as continuing forward despite limitations.

Furthermore, dreams and plans are often reshaped. The future you once imagined may no longer look the same. Some goals may need to be delayed, adjusted, or even let go. Nevertheless, this does not mean that dreams disappear; rather, they evolve. New paths are created, and success begins to take on a different, more personal meaning.

Daily life, too, becomes different. Routines are no longer just routines—they involve medications, doctor visits, energy management, and careful decisions about what the body can handle each day. Because of this, even small accomplishments begin to hold deeper value, and rest becomes just as important as progress.

Financial aspects can also be affected. Treatments, medications, and ongoing care can create added pressure, making it necessary to plan, adjust, and sometimes sacrifice. In this way, the illness extends beyond health and into practical realities, shaping how resources are managed and priorities are set.

Social life and experiences may also change. There may be events you cannot attend, activities you need to limit, or moments when your energy simply isn’t enough. Although this can feel isolating at times, it can also lead to a deeper appreciation for meaningful connections and genuine moments.

Even identity itself can be influenced. You may begin to see yourself not just as who you were before, but as someone who has endured, adapted, and grown through challenges. While the illness becomes part of your story, it does not erase who you are—it adds depth, strength, and perspective.

And yet, despite all these changes, there is still life beyond the illness. Scleroderma may affect everything, but it does not define everything. Within the struggles, there is courage. Within the uncertainty, there is hope. And within every limitation, there is still the ability to find meaning, connection, and purpose. 🙏💪



*INVITACIÓN A PARTICIPAR EN EL ESTUDIO CLÍNICO CONQUEST*¿Tienes esclerodermia y estás buscando nuevas opciones de tratam...
27/03/2026

*INVITACIÓN A PARTICIPAR EN EL ESTUDIO CLÍNICO CONQUEST*

¿Tienes esclerodermia y estás buscando nuevas opciones de tratamiento? El estudio CONQUEST es un estudio clínico de Fase 2b que busca evaluar la seguridad y eficacia de Amlitelimab y Nerandomilast en pacientes con enfermedad pulmonar intersticial secundaria a la esclerosis sistémica.

*¿Eres elegible?*

- Tienes al menos 18 años
- Diagnóstico de esclerodermia hace menos de 5 años (excluyendo Raynaud)
- mRSS entre 10-35 puntos
- Compromiso pulmonar ≥10%
- FVC entre 45-80%

*¿Qué implica participar?*

- Recibirás tratamiento con Amlitelimab, Nerandomilast o placebo durante 52 semanas
- Visitas regulares con el equipo de investigación
- Monitoreo de la función pulmonar y seguridad

*¿Interesado?*

Contacta con la Dra. Tatiana R. Rodríguez o la Dra. Adriana Miguel Álvarez:
- Correo: tatiana.rodriguezr@incmnsz.mx o adriana.miguela@incmnsz.mx
- Teléfono: 55 8028 2089

¡Únete al estudio CONQUEST y ayúdanos a encontrar nuevas opciones de tratamiento para la esclerodermia!

27/03/2026

Join us for an educational program designed to provide clear, practical information on managing scleroderma! 💙

Learn about treatment options. Connect with trusted experts and local support resources.

This event is ideal for patients, caregivers, and anyone looking to better understand scleroderma!

🔗 Register today: https://bit.ly/SclerodermaInsightsJax

27/03/2026

People living with autoimmune disease are often misunderstood because many of their symptoms cannot be seen. Although others may not notice what they are going through, fatigue, pain, and sudden loss of energy are very real. Because of this, when someone needs to slow down or rest more than usual, it should not be mistaken for laziness but understood as the body coping with daily physical challenges.

In the same way, individuals living with scleroderma often face changes in their energy and strength throughout the day. As a result, even simple tasks can require extra effort and patience. Sometimes plans need to be adjusted, and at other times rest becomes necessary to manage symptoms and prevent worsening conditions. Therefore, choosing to pause is part of protecting health and continuing forward.

For this reason, people with invisible illnesses deserve understanding and compassion. Even if their struggles are not always visible, they are still trying their best each day. Instead of judging what cannot be seen, it is important to recognize their effort and resilience, because they are not lazy but quietly doing their best to keep going. 💪



20/03/2026

Nintedanib is a medication commonly used in the management of lung complications associated with Systemic Sclerosis (scleroderma), particularly in patients who develop interstitial lung disease (ILD). In systemic sclerosis, progressive fibrosis (scarring) of lung tissue can impair oxygen exchange and lead to declining lung function over time. This complication is one of the leading causes of morbidity and mortality in affected individuals.

Nintedanib works as a tyrosine kinase inhibitor that targets multiple pathways involved in fibrosis. It blocks receptors such as platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF), all of which play a role in the activation and proliferation of fibroblasts. By inhibiting these pathways, nintedanib helps reduce the formation of scar tissue in the lungs and slows the progression of fibrosis.

In patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), this antifibrotic action helps preserve lung function by slowing the rate of decline in forced vital capacity (FVC), a key measure of lung capacity. While nintedanib does not reverse existing fibrosis, it plays an important role in limiting further lung damage and maintaining respiratory function over time.

Clinical studies, including the SENSCIS trial, have demonstrated that nintedanib significantly reduces the rate of lung function decline in patients with SSc-ILD. Patients receiving nintedanib showed slower progression of disease compared to those receiving placebo. This benefit makes it a valuable option in managing fibrotic lung involvement in systemic sclerosis.

International treatment guidelines, including those from the European Alliance of Associations for Rheumatology (EULAR), recognize nintedanib as an important therapy for systemic sclerosis-associated interstitial lung disease. It is often considered in patients with progressive lung fibrosis and may be used alongside immunosuppressive agents such as mycophenolate mofetil to provide a more comprehensive treatment approach.

Despite its benefits, nintedanib can cause side effects that require monitoring. The most common adverse effect is diarrhea, which can be significant in some patients. Other side effects include nausea, vomiting, abdominal pain, decreased appetite, weight loss, and elevated liver enzymes. Because of potential liver toxicity, regular monitoring of liver function tests is recommended during treatment.

Overall, nintedanib has become an important therapy for managing lung fibrosis in systemic sclerosis. Although it does not address the underlying autoimmune process of the disease, it plays a crucial role in slowing disease progression, preserving lung function, and improving long-term outcomes in patients with interstitial lung involvement.

References:
European Alliance of Associations for Rheumatology (2024). EULAR recommendations for the treatment of systemic sclerosis. Annals of the Rheumatic Diseases.
Distler, Oliver et al. (2019). Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease. The New England Journal of Medicine.

Disclaimer:
This post is for educational and awareness purposes only and does not constitute medical advice. Nintedanib is a prescription medication that should only be used under the supervision of qualified healthcare professionals. Treatment decisions should always be made in consultation with physicians experienced in systemic sclerosis and its complications.



Ensayo clínico
19/03/2026

Ensayo clínico

Tu respiración también puede estar en riesgo… 🫁

Muchas personas creen que las enfermedades autoinmunes solo afectan articulaciones o la piel… pero la realidad es otra: también pueden comprometer los pulmones.

En el lupus, el sistema inmune ataca tejidos sanos y puede inflamar la pleura (la capa que recubre los pulmones), generando dolor al respirar, falta de aire o sensación de opresión.

En la artritis reumatoide, no solo se inflaman las articulaciones… también pueden aparecer cambios en el tejido pulmonar, volviéndolo más rígido (fibrosis), lo que limita la capacidad de expandirse correctamente.

Y en enfermedades como el síndrome de Sjögren, la sequedad no es solo en ojos o boca… también puede afectar las vías respiratorias, generando irritación constante y dificultad para respirar.

¿Por qué ocurre esto?
Porque estas condiciones no son locales… son sistémicas. El sistema inmune pierde la capacidad de reconocer lo propio y empieza a atacar diferentes órganos, incluyendo los pulmones.

El problema es que muchas veces estos síntomas pasan desapercibidos… hasta que la respiración ya no es la misma.

Aquí es donde el enfoque cambia.
No se trata solo de calmar síntomas… sino de trabajar el terreno celular, reducir el estrés oxidativo y apoyar al sistema inmune desde adentro.

Si tienes alguno de estos síntomas o ya tienes un diagnóstico, es momento de mirar más profundo.

Escríbeme “PROTOCOLO” por interno y te explico cómo empezar a trabajar tu cuerpo desde la raíz 🔬

Dirección

Mexico City

Notificaciones

Sé el primero en enterarse y déjanos enviarle un correo electrónico cuando Asociación Mexicana de Orientación, Apoyo y Lucha Contra la Esclerodermia publique noticias y promociones. Su dirección de correo electrónico no se utilizará para ningún otro fin, y puede darse de baja en cualquier momento.

Contacto El Consultorio

Enviar un mensaje a Asociación Mexicana de Orientación, Apoyo y Lucha Contra la Esclerodermia:

Compartir

Categoría